Navigation Links
CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a "ChamPIon"

KING OF PRUSSIA, Pa., Dec. 13, 2012 /PRNewswire/ -- CSL Behring has teamed up with Professional Supercross racer Carl Schlacht to launch This new online resource is part of the I am a ChamPIon campaign, a partnership that aims to raise awareness of primary immunodeficiency disease (PI or PIDD) while encouraging those with the condition to pursue their dreams despite the challenges that PI can pose. 

"PI is a genetic disorder that can have a dramatic impact on a person's ability to participate in daily activities due to a weakened immune system that leaves him or her vulnerable to common infections. If PI is left untreated, infections can occur – some severe enough to cause permanent and irreversible organ damage," said Dr. John Sleasman, Chief of the Division of Pediatric Allergy, Immunology and Rheumatology at the University of South Florida. "While the condition is not curable, immunoglobulin treatments can help supplement the immune system to allow patients to lead active lives."

Carl is just one of approximately 250,000 individuals (or one in 1,200) diagnosed with PI in the United States. Race fans watching Carl perform high flying jumps and difficult maneuvers would never know that he requires a weekly subcutaneous infusion (i.e., under the skin) of immunoglobulin to manage his condition, which helps him stay healthy to compete at the professional level.

"Growing up I didn't know anyone else affected by primary immunodeficiency," said Carl, who was diagnosed with PI at a year old. "For this reason, I am encouraging everyone affected by PI to visit and post their 'ChamPIon' story. Collectively, we can support and inspire each other to pursue our dreams." 

In addition to providing an outlet for people with PI to share their stories, the I Am a ChamPIon website offers information about the condition and identifying the warning signs for diagnosis. At you can also watch a video of Carl on the race track and discussing his journey to becoming a professional Supercross racer despite PI.  

About Primary Immunodeficiencies   
Nearly 150 types of PIs exist. For individuals with PI, many of them children, infections may not improve as expected with usual treatments and may even keep returning. As a result, patients may face repeated rounds of antibiotics or hospitalization for treatment. Repeated infections can lead to organ damage, which over time can become life-threatening. Some infections, such as meningitis, may even result in death.

Collectively, PIs affect an estimated 10 million people worldwide. Due to the X-linked inheritance in many PI syndromes, more males are affected than females.  For more information on PI, please visit or contact the leading PI patient advocate groups in the U.S., the Immune Deficiency Foundation and the Jeffrey Modell Foundation.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited  (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit

Media Contacts:
Greg Healy
Senior Manager, Public Relations & Communications
CSL Behring

Etanjalie Ayala
Weber Shandwick

Judy Welage
Weber Shandwick

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care
2. CSL Behring Study Confirms Early Treatment with Berinert® Provides Faster Resolution of Acute Hereditary Angioedema Symptoms
3. Medical Experts Who Participated in CSL Behrings Key Issues Dialogue Prefer Albumin for Fluid Management
4. CSL Behring Awards LEAD Grant to Patient Organizations to Educate Constituents on State Insurance Exchanges
5. CoreLab Partners, Medical Image Assessment Experts, Announces Its Entry Into the Early Alzheimers Imaging Market Space
6. Veterinary Bioscience Institute (VBI) and a-tune software, Inc. Partnership
7. Chimerix To Present At Therapeutic Area Partnerships Meeting
8. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
9. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
10. Bluechiip Signs Strategic Partnership with Gentris Corporation
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
Breaking Biology News(10 mins):